GPE – Page 11 – Talk Bio

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Novartis to invest $23B in manufacturing so ‘all key medicines’ can be made in the US

5 months ago talkbio0Tagged Biological Factors, Investments, Manufacture, Novartis, production, United States

Novartis, United States, Investments, Manufacture, production, Biological Factors, Novartis

Pharma stocks swerve as Trump hits pause on most tariffs

5 months ago talkbio0Tagged Market, Pauses, Transplant Registry Unified Management Program

Market, Transplant Registry Unified Management Program, Pauses

Global Pharmaceutical Stocks Plummet Amid Trump’s Imminent Tariff Threats

5 months ago talkbio0Tagged chain disruption, drug manufacturing, Generalized, pharma policy, pharmaceutical tariffs, pharmaceutical trade war, Trump import tariffs, United States

Pharmaceutical tariffs, global pharma stocks, Trump import tariffs, drug manufacturing, supply chain disruption, pharmaceutical trade war, U.S. pharma policy

Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling

5 months ago talkbio0Tagged Administration occupational activities, Administrative Procedure Act, appeal, CHARGE Syndrome, federal judge, Health Policy, Indirect, injunction, Legal, Medical Research activity, NIH Mouse, Permanent, research, Transplant Registry Unified Management Program, U.S., United States

NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.

Annexon Advances Guillain-Barré Syndrome Awareness and Introduces Groundbreaking Targeted Therapy

5 months ago talkbio0Tagged Annexon, ANX005, Approved, GBS, Guillain-Barré syndrome, Move GBS Forward™, Phase 3, Phase 3 trial, Tanruprubart, Targeted Therapy, United States Food and Drug Administration

Guillain-Barré Syndrome (GBS) , Annexon , Tanruprubart (ANX005) , Targeted therapy , GBS education campaign , Move GBS Forward™ , Phase 3 trial results , FDA approval

Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing

5 months ago talkbio0Tagged drug price, Impact food supplement, Pharma import taxes, pharmaceutical manufacturing, Pharmaceutical stocks, pharmaceutical tariffs, Policy, Relations, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.-China, United States

Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks